idoBR1 Plant Extract Standardization With Functional Bioactivity Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The complex nature and non-uniformity of herbal food additives and supplements derived from plant materials make it difficult to standardize and control the quality, particularly due to the lack of detailed monographs and uniform extraction procedures, leading to inconsistencies in bioactive principles.
Innovation Solution
A process is developed to produce a composition comprising (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid (idoBR1) by fractionating plant material from the Cucurbitaceae family, assaying for inhibitory activity against sialidase or TNF-alpha, or IL-10 stimulatory activity, and formulating the extract with a suitable excipient to create a cosmetic, nutraceutical, or pharmaceutical composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional herbal extracts are used without standardized procedures, then product variety and flexibility are maintained, but quality consistency and manufacturing precision deteriorate
Solution Approach 1:
The patent applies parameter changes by establishing specific quantitative parameters for quality control including minimum idoBR1 content (≥0.1% w/w), extraction solvent composition (5-95% v/v alcohol), extraction temperature ranges (20-80°C), and assay thresholds (IC50 ≤ 100 μg/mL for sialidase inhibition). These standardized parameters enable consistent manufacturing across different batches while maintaining the ability to produce various product forms (extracts, isolates, formulations).
Solution Approach 2:
The patent segments the quality control process into distinct operational stages: extraction phase with controlled parameters, concentration phase with defined solvent removal criteria, assay phase with specific biological activity thresholds, and formulation phase with standardized dosage forms. This segmentation allows each stage to be optimized independently while ensuring overall quality consistency.
2Manufacturing precision
If detailed monographs and uniform extraction procedures are implemented, then manufacturing precision and quality control improve, but device complexity and process complexity increase
Solution Approach 1:
The patent extracts and isolates the key quality-determining parameter (idoBR1 content and biological activity) from the complex herbal matrix. By focusing quality control on this specific active principle through targeted extraction procedures using alcohol-water solutions and subsequent concentration to defined solvent residue levels, the patent simplifies quality assurance without requiring control of all plant constituents.
Solution Approach 2:
The patent applies preliminary action by pre-establishing standardized monographs that define extraction parameters, quality thresholds, and assay methods before production begins. These pre-defined protocols include specific solvent compositions, temperature ranges, extraction times, and minimum active principle concentrations, eliminating the need for complex real-time adjustments during manufacturing.
3Measurement precision
If physical characterization methods are used extensively, then measurement precision and quality verification improve, but production time and productivity decrease
Solution Approach 1:
The patent replaces extensive physical characterization methods (chromatography, spectroscopy, mass spectrometry) with a simplified biological assay system that measures functional activity (sialidase inhibition IC50, TNF-alpha inhibition, IL-10 stimulation). This substitution maintains quality verification rigor by assessing the actual biological effect of idoBR1 while dramatically reducing analysis time and equipment requirements.
Solution Approach 2:
The patent uses biological assay systems that replicate the physiological action of idoBR1 in simplified model systems (enzyme inhibition assays, cytokine production assays). These functional copies of the biological activity provide sufficient quality verification without requiring complete structural characterization, enabling faster quality release.
Data Source
AI summary
Described are processes for the production of a composition comprising (2R, 3R, 4R, 5S)-3, 4, 5-trihydroxypiperidine-2-carboxylic acid (idoBR1), said process comprising the steps of: a) providing plant material from a botanical source comprising plant of the family Cucurbitaceae; b) fractionating said plant material to produce an extract enriched in idoBR1 c) assaying said extract for: i) inhibitory activity against sialidase or TNF-alpha or ii) IL-10 stimulatory activity; and d) formulating said assayed extract with a cosmetically-, nutraceutically- or pharmaceutically-acceptable excipient or carrier to produce a cosmetic, nutraceutical or pharmaceutical composition.